ORGO Organogenesis Holdings Inc.

CIK 0001661181 41 ready 8-Ks latest August 6, 2026, 4:45 PM ET RSS · JSON

Activity: NORMAL 2 filings / 30d vs 1 baseline

Ready 8-Ks 41

Latest filing August 6, 2026, 4:45 PM ET

Top materiality 0.90

Event mix earnings ×21 · other_material ×11 · other ×4

Sentiment 11 pos · 12 neg · 18 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for ORGO

Highest-materiality recent filing

Organogenesis Q2 revenue down 58% to $42.8M; net loss widens to $96.3M; FY guidance slashed

August 6, 2026, 4:11 PM ET earnings materiality 0.90 negative item 2.02 item 9.01

Net revenue $42.8M vs $100.8M YoY; Advanced Wound Care fell 61% to $36.1M.
Net loss $96.3M ($0.77/share) vs $9.4M loss ($0.10/share) in Q2 2025.

Read filing →

August 6, 2026, 4:45 PM ET other material materiality 0.60 neutral item 1.01 item 9.01

Organogenesis enters $75M at-the-market equity distribution agreement with BTIG and Citizens JMP

Up to $75M of Class A common stock may be sold from time to time through BTIG and Citizens JMP Securities.
August 6, 2026, 4:11 PM ET earnings materiality 0.90 negative item 2.02 item 9.01

Organogenesis Q2 revenue down 58% to $42.8M; net loss widens to $96.3M; FY guidance slashed

Net revenue $42.8M vs $100.8M YoY; Advanced Wound Care fell 61% to $36.1M.
May 7, 2026, 7:59 PM ET earnings materiality 0.80 negative item 2.02 item 9.01 ◈ Earnings Releases

Organogenesis Q1 revenue $36.3M (-58% YoY); net loss $53.2M; FY guidance lowered

Net revenue $36.3M, down 58% YoY from $86.7M; Advanced Wound Care down 63% to $29.5M.
February 26, 2026, 6:59 PM ET earnings materiality 0.85 negative item 2.02 item 9.01

Organogenesis reports record Q4 2025 revenue $225M; FY2026 guidance implies 25-38% decline

Q4 2025 net product revenue $225.1M (+78% YoY); Advanced Wound Care $217.2M (+83% YoY).
November 6, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Organogenesis posts record Q3 revenue of $150.5M, raises FY2025 guidance

Net product revenue $150.5M (+31% YoY); Advanced Wound Care $141.5M (+31%), Surgical & Sports Med $9.0M (+25%).
September 25, 2025, 7:59 PM ET other material materiality 0.80 negative item 7.01 item 8.01 item 9.01

Organogenesis second Phase 3 ReNu knee OA trial misses primary endpoint; pre-BLA meeting planned

Second Phase 3 (n=594) did not meet primary endpoint: WOMAC pain reduction difference -0.5 favoring ReNu (p=0.0393 vs target p=0.023).
August 7, 2025, 7:59 PM ET earnings materiality 0.85 negative item 1.01 item 2.02 item 9.01

Organogenesis Q2 revenue down 23% to $100.8M; amends credit agreement, waives covenant test

Net product revenue $100.8M (down 23% YoY); Advanced Wound Care fell 25%, Surgical & Sports Med up 16%.
June 24, 2025, 7:59 PM ET other material materiality 0.60 neutral item 5.02 item 5.07

Organogenesis stockholders approve Series A conversion issuance and director elections at 2025 annual meeting

Stockholders approved issuance of >20% of Class A common stock upon conversion of Series A Preferred at less than Nasdaq minimum price.
May 8, 2025, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

Organogenesis Q1 revenue down 21% to $86.7M; net loss widens to $18.8M; FY guidance reaffirmed

Net revenue $86.7M, down 21% YoY; Advanced Wound Care fell 23% to $79.9M; Surgical & Sports Medicine up 11% to $6.8M.
February 27, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Organogenesis Q4 revenue up 27% to $126.7M; net income $7.7M vs loss year ago; guides FY25 rev $480-535M

Q4 net revenue $126.7M (+27%); Advanced Wound Care $118.6M (+27%), Surgical/Sports $8.1M (+24%).
November 13, 2024, 6:59 PM ET other material materiality 0.80 positive item 1.01 item 5.03 item 2.04 item 3.02 item 3.03 item 5.02 item 8.01 item 9.01 ◈ executive_change

Organogenesis raises $130M convertible preferred, repurchases 7.4M shares, appoints Avista director

Sold 130,000 shares of Series A Convertible Preferred Stock at $1,000/share for gross proceeds of $130M.
November 12, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Organogenesis Q3 revenue up 6% to $115.2M, net income $12.3M vs $3.2M; updates FY guidance

Net revenue $115.2M (+6% YoY); Advanced Wound Care $108.0M (+7%).
August 8, 2024, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

Organogenesis Q2 revenue up 11% but net loss $17M on $22.8M impairment and write-downs

Net revenue $130.2M (+11% YoY); Advanced Wound Care $123.2M (+12%), Surgical & Sports Med $7.0M (-3%).
May 9, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01 ◈ Earnings Releases

Organogenesis beats Q1 revenue guidance with $110.0M; net loss narrows to $2.1M

Net revenue $110.0M, up 2% YoY, exceeding high-end of FY2024 guidance.
February 29, 2024, 6:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01 ◈ Earnings Releases ×2

Organogenesis Q4 revenue $99.7M (-14% YoY); net loss $0.6M; FY2024 guides $445M-$470M

Net revenue Q4 $99.7M (-14% YoY): Advanced Wound Care $93.2M (-14%), Surgical & Sports Medicine $6.5M (-3%).
November 9, 2023, 6:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

Organogenesis Q3 revenue down 7% to $108.5M; net income rises to $3.2M; guides FY rev down 1-4%

Net revenue $108.5M, down $8.3M YoY; Advanced Wound Care fell 7% to $101.4M; Surgical & Sports Med fell 2% to $7.2M.
August 9, 2023, 7:59 PM ET earnings materiality 0.80 negative item 2.02 item 9.01 ◈ Earnings Releases ×2

Organogenesis Q2 revenue $117.3M (-3% YoY); withdraws FY2023 guidance on Medicare LCDs

Net revenue of $117.3M, down 3% YoY from $121.4M; net income $5.3M vs $8.7M.
May 10, 2023, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 9.01 ◈ Earnings Releases

Organogenesis Q1 rev $107.6M (+11% YoY); raises FY2023 revenue to $454-466M

Net revenue $107.6M, up 11% YoY; net loss $3.0M vs $0.9M loss year-ago.
March 1, 2023, 6:59 PM ET earnings materiality 0.80 negative item 2.02 item 9.01 ◈ Earnings Releases ×2

Organogenesis Q4 revenue down 10% YoY; FY2023 guidance flat to +2%

Q4 2022 net revenue $115.5M (-10% YoY); net income $7.5M vs $51.0M in Q4 2021.
November 9, 2022, 6:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01 ◈ Earnings Releases

Organogenesis Q3 net income plummets to $0.2M on $116.9M revenue; cuts FY2022 guidance

Net revenue $116.9M (+3% YoY), but net income $0.2M vs $12.6M in Q3 2021.
August 9, 2022, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Organogenesis Q2 revenue $121.4M (-1% YoY); net income falls 58% to $8.7M

Net revenue $121.4M vs $123.2M in Q2 2021; adjusted revenue up 3% excluding ReNu/NuCel.
May 10, 2022, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

Organogenesis Q1 revenue down 4% to $98.1M; net income drops to $0.1M from $9.9M

Net revenue $98.1M, down 4% YoY; adjusted net income $1.2M vs $11.2M.
March 1, 2022, 6:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01

Organogenesis Q4 revenue $128.6M (+20% YoY), FY22 guidance $485M-$515M

Q4 net revenue $128.6M (up 20% YoY); Advanced Wound Care $121.4M (+30%), Surgical & Sports Medicine $7.2M (-45%).
November 9, 2021, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Organogenesis Q3 revenue $113.8M (+13% YoY), net income $12.6M, FY2021 guidance $458-470M

Net revenue $113.8M (+13% YoY); Advanced Wound Care $107.3M (+19%), Surgical & Sports Medicine $6.4M (-41%).
August 16, 2021, 7:59 PM ET other material materiality 0.65 neutral item 1.01 item 1.02 item 9.01

Organogenesis buys Canton facility for $6M from directors/stockholders; terminates lease

Purchased land and building at 275 Dan Road, Canton, MA for $6M cash from seller owned by directors/stockholders.
August 9, 2021, 7:59 PM ET earnings materiality 0.85 positive item 1.01 item 1.02 item 2.02 item 2.03 item 7.01 item 9.01

Organogenesis Q2 revenue $123.2M (+79%), net income $20.7M; new $200M credit facility

Net revenue $123.2M (+79% YoY); Advanced Wound Care $111.4M (+87%), Surgical & Sports Med $11.8M (+27%).